Mario Germano Giuliani and Lisa Giuliani have made an extraordinary gift of $27.8 million to support research in multiple myeloma, Dana-Farber Cancer Institute announced today. It is one of the ...
New research from Dana-Farber Cancer Institute scientists suggests that cyclin-dependent kinase 2 (CDK2) inhibitors, which are currently being tested as treatments that slow the growth of a narrow ...
Dana-Farber/New Hampshire Oncology-Hematology provides expert cancer care in Londonderry, NH. The center makes it possible to offer the expertise and experience of Dana-Farber, New England's leading ...
Take a video tour of Dana-Farber Cancer Institute - Chestnut Hill, a multi-disciplinary hospital facility located in the Chestnut Hill area of Newton, MA. It is available in English, Spanish, ...
Pancreatic and biliary cancers are challenging diseases. At the Pancreas and Biliary Tumor Center, our specialists are making breakthrough discoveries in every discipline: Thomas E. Clancy, MD, is a ...
The Dana-Farber Brigham Cancer Center Kidney Cancer team is composed of leaders in the field who are committed to providing you with the highest level of patient care. Our multidisciplinary team of ...
Dr. Ted Hong is the Vice Chair of Integration and Collaboration in Radiation Oncology at Beth Israel Deaconess Medical Center and Dana-Farber Cancer Institute, and Associate Chief of Procedure-based ...
Daraxonrasib is the first approved RAS-targeted therapy in pancreatic cancer Approval based primarily on Dana-Farber-led RASolute 302 trial showing daraxonrasib nearly doubled med ...
If you are a journalist and have a question about this story, please call 617-632-4090 and ask to speak to a member of the media team, or email media@dfci.harvard.edu.
Marijuana smoking found to raise levels of potentially harmful chemicals but to a lesser degree than tobacco smoking Exposure to a toxic chemical associated with heightened risk for cardiovascular ...
Dana-Farber Cancer Institute has implemented an artificial intelligence (AI) application intended for general use in a medical center or hospital. The system, called GPT4DFCI, is permitted for ...
The U.S. Food and Drug Administration (FDA) approved revumenib, a first-in-class oral menin inhibitor, for the treatment of adults and children one year and older with relapsed or refractory acute ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results